Table 4.
Treatment |
AST (U/L) |
ALT (U/L) |
GGT (U/L) |
ALP (U/L) |
Bilirubin (mg/dl) |
|||||
---|---|---|---|---|---|---|---|---|---|---|
Mean ± S.E | % Change | Mean ± S.E | % Change | Mean ± S.E | % Change | Mean ± S.E | % Change | Mean ± S.E | % Change | |
Control | 98.36 ± 4.48 | 31.55 ± 2.91 | 4.40 ± 0.25 | 332.16 ± 9.48 | 0.59 ± 0.01 | |||||
CCl4 | 384.66 ± 7.95***a | 300.00 ± 12.02**a | 14.55 ± 0.55*** a | 595.83 ± 11.88*** a | 3.09 ± 0.09*** a | |||||
Silymarin (10 mg/kg) | 192.00 ± 6.78***b | 50.08 | 98.06 ± 5.14*** b | 67.31 | 7.20 ± 0.24*** b | 50.51 | 425.83 ± 13.93*** b | 28.53 | 1.11 ± 0.09*** b | 63.90 |
3 (10 mg/kg) | 225.83 ± 9.77***b | 41.29 | 184.83 ± 5.22*** b | 38.38 | 11.13 ± 0.24*** b | 23.48 | 554.33 ± 6.12* b | 6.88 | 2.76 ± 0.10* b | 10.86 |
4 (12 mg/kg) | 245.00 ± 11.89***b | 36.30 | 168.66 ± 5.49***b | 43.77 | 9.48 ± 0.43*** b | 34.82 | 474.83 ± 11.93***b | 20.30 | 1.67 ± 0.18*** b | 45.99 |
7 (14 mg/kg) | 290.00 ± 7.42***b | 24.61 | 221.16 ± 8.37*** b | 28.77 | 9.01 ± 0.35*** b | 38.02 | 452.83 ± 12.79*** b | 24.00 | 1.49 ± 0.09*** b | 51.64 |
8 (14 mg/kg) | 350.33 ± 9.51*b | 8.92 | 302.83 ± 5.33b | – | 13.38 ± 0.41b | 8.01 | 592.33 ± 8.53b | – | 2.97 ± 0.06b | 4.14 |
Silymarin (10 mg/kg) | 139.00 ± 7.16***b | 53.15 | 77.62 ± 16.46***b | 65.53 | 6.50 ± 0.30***b | 56.73 | 411.50 ± 25.10***b | 31.01 | 1.04 ± 0.12***b | 64.27 |
4 (18 mg/kg) + 7 (21 mg/kg) | 189.50 ± 7.18***b | 36.14 | 142.00 ± 5.78***b | 36.95 | 11.47 ± 0.38***b | 23.62 | 434.50 ± 6.80***b | 27.15 | 1.46 ± 0.03***b | 50.21 |
All values represent mean ± SEM. *p < 0.05; **p < 0.01; ***p < 0.001; ANOVA, followed by Dunnett's multiple comparison test.
As compared with Control group.
As compared with CCl4 only group.